Translating Immunology Discoveries into Therapies: Inaugural Ross Prize in Molecular Medicine

FREE

for Members

Translating Immunology Discoveries into Therapies: Inaugural Ross Prize in Molecular Medicine

Monday, June 24, 2013

The New York Academy of Sciences

 

The annual Ross Prize in Molecular Medicine is established in conjunction with the Feinstein Institute for Medical Research and Molecular Medicine. The winner is an active investigator having produced innovative, paradigm-shifting research that is worthy of significant and broad attention in the field of molecular medicine. This scientist will continue to garner recognition in future years, and their current accomplishments reflect a rapidly rising career trajectory of discovery and invention.

In recognition as a leader in the fields of immunology and virology, Dr Dan R. Littman will receive the Inaugural Ross Prize in Molecular Medicine.

This symposium will honor Dr Littman, who will reflect upon his early discoveries and ongoing research to better understand viral, immune, and inflammatory diseases. Following the award presentation, leading scientists in immunology will discuss new insights in the mechanism of immune system function and signaling that provide clues to the prevention or treatment of autoimmune and inflammatory diseases.

Registration Pricing

Symposium registration is free and advance registration is required.


This symposium is made possible with support from

  • Feinstein Institute

Agenda

* Presentation titles and times are subject to change.


Monday, June 24, 2013

10:30 AM

Registration and Refreshments

11:00 AM

Welcome and Introductory Remarks
Brooke Grindlinger, PhD, Executive Director, Scientific Programs, The New York Academy of Sciences
Michael J. Dowling, President & CEO, North Shore-Long Island Jewish Health System
Jack and Robin Ross

Session I: Inaugural Ross Prize in Molecular Medicine Presentation

11:10 AM

Inaugural Ross Prize in Molecular Medicine Announcement and Presentation
Betty Diamond, MD, Ross Prize Committee, The Feinstein Institute for Medical Research

11:30 AM

Inaugural Ross Prize in Molecular Medicine Acceptance and Lecture
Dan R. Littman, MD, PhD, New York University School of Medicine

11:45 AM

Press Briefing

Luncheon

Session II: Inaugural Ross Prize in Molecular Medicine Lectures

1:00 PM

Differentiation and Function of Regulatory T Cells
Alexander Rudensky, PhD, Memorial Sloan-Kettering Cancer Center

1:30 PM

Compartmentalized Control of Tissue Immunity by Commensals
Yasmine Belkaid, PhD, National Institute of Allergy and Infectious Diseases, NIH

2:00 PM

Shaping of the Systemic Immune Repertoire by the Intestinal Microbiota
Dan R. Littman, MD, PhD, New York University School of Medicine

2:45 PM

Closing Remarks
Kevin J. Tracey, MD, President, The Feinstein Institute for Medical Research

3:00 PM

Adjourn

Speakers

Featured Speakers

Yasmine Belkaid, PhD

National Institute of Allergy and Infectious Diseases, NIH

Dan R. Littman, MD, PhD

New York University School of Medicine

Dr Littman is the Helen L. and Martin S. Kimmel Professor of Molecular Immunology, a Professor in the Departments of Pathology and of Microbiology, and a faculty member in the Molecular Pathogenesis program in the Skirball Institute of Biomolecular Medicine at New York University School of Medicine.

A renowned immunologist, Dr Littman has made seminal contributions in a number of scientific fields, advancing our understanding of the molecular basis of immune recognition, HIV pathogenesis, T-cell differentiation and selection, and, most recently, the role of commensal bacteria in immune system development and regulation. Among his many honors, Dr Littman is a Howard Hughes Medical Institute Investigator and a member of the National Academy of the Sciences. Most recently, Dr Littman was elected into the Institute of Medicine, a further demonstration of his remarkable and important contributions to both science and medicine.

Over the past 25 years, Dr Littman has been a recognized leader in the fields of immunology and virology. Early on, Dr Littman isolated the genes coding the CD4 and CD8 co-receptors and determined how their expression is regulated and their signaling influences selection of helper and cytotoxic T cells. His group went on to demonstrate that CD4 and CCR5 serve as co-receptors for HIV infection of immune cells, leading to therapeutic targeting of CCR5 in AIDS. More recently, Dr Littman, in collaboration with a team of Dutch scientists, discovered that the HIV virus enters the body via what he terms "a Trojan horse" — immature dendritic cells. HIV evades host innate responses by failing to replicate in dendritic cells, but it is through these cells that the virus gains access to the immune system, invading and gradually disabling helper T cells. Without helper T cells, the body can't fight off HIV and is vulnerable to opportunistic infections. These seminal discoveries have expanded our understanding of the mechanisms by which the HIV virus subverts host immune responses and reveal new targets for therapeutic intervention in this disease.

The scope and impact of Dr Littman's work expands far beyond the field of the immune response to HIV infection. He and his team discovered that the nuclear receptor RORγt is the key transcriptional regulator of the differentiation of Th17 cells and lymphoid tissue inducer cells: they also identified compounds that inhibit RORγt activity and may be effective for the treatment of autoimmune and inflammatory diseases in which Th17 cells play a pathologic role. He has further identified a commensal gut bacterium that selectively induces Th17 cells and promotes autoimmunity in mice; this may be relevant for human diseases, like rheumatoid arthritis, that are thought to be influenced by imbalanced microbiota.

Dr Littman's research has considerable translational potential, and is already being translated into therapies for a number of viral, immune, and inflammatory diseases. His studies of the mechanisms by which HIV and other microbes evade detection by the immune system and interact with immune cells and proteins to ensure their survival will ultimately allow for the development of better strategies to combat HIV infection. His studies of immune system signaling and development provide clues to ways to manipulate immune cells to prevent or treat autoimmune and inflammatory diseases and to develop better vaccines against microbial pathogens and cancer.

Alexander Rudensky, PhD

Memorial Sloan-Kettering Cancer Center

Alexander Rudensky is Chairman of the Immunology Program at Memorial Sloan‐Kettering Cancer Center (MSKCC), an Investigator with the Howard Hughes Medical Institute, and a Tri‐Institutional Professor at MSKCC, the Rockefeller University and Cornell University, and Professor at Gerstner School of Graduate Studies and at Weill‐Cornell Medical School. Prior to his joining MSKCC, he was Professor of Immunology at the University of Washington School of Medicine, Seattle. Dr. Rudensky received his PhD degree from the Gabrichevsky Research Institute of Epidemiology and Microbiology, Moscow and postdoctoral training at Yale University Medical School with the late Dr. Charles A. Janeway, Jr. Dr. Rudensky‘s current research is focused on the development of T lymphocytes, and investigating their function and role in the regulation of immune responses to infection, inflammation and in the prevention of autoimmunity; and to develop novel means of tumor immunotherapy and intervention with a wide range of autoimmune and inflammatory diseases, and chronic infections. He is a member of numerous advisory and editorial boards including Cell, Immunity, Cancer Research Institute and Damon Cancer Research Foundation. He serves also as an Editor of the Journal of Experimental Medicine. Dr. Rudensky is the recipient of numerous awards including Searle Scholar Award and in 2012 was elected to the National Academy of Sciences. Dr. Rudensky has authored over 150 peer-reviewed publications.

*Additional bio to follow.

Sponsors

This symposium is made possible with support from

  • Feinstein Institute

Abstracts

Differentiation and Function of Regulatory T Cells
Alexander Rudensky, PhD, Howard Hughes Medical Institute/Memorial Sloan-Kettering Cancer Center, New York, New York

In multicellular organisms, a balance between pro- and anti-inflammatory immune mechanisms affords protection from infectious agents and unintended consequences of the immune response resulting in a lasting or transient loss of tissue function. Regulatory T cells prevent systemic and tissue-specific autoimmunity and inflammatory lesions at mucosal interfaces as well as sterile metabolic inflammation. Genetic deficiency in Foxp3, a key transcription factor specifying fate and function of regulatory T cells, leads to their paucity and consequent fatal aggressive lympho- and myelo-proliferative syndrome. Regulatory T cells are generated in the thymus and extrathymically. The dual origin of these cells implies a division of labor and suggests that they have discernible non-redundant functions in immune homeostasis in different biological settings. Mechanisms of differentiation and function of regulatory T cells of thymic and extrathymic origin will be discussed.

Shaping of the Systemic Immune Repertoire by the Intestinal Microbiota
Dan R. Littman, MD, PhD, Howard Hughes Medical Institute, The Kimmel Center for Biology and Medicine of the Skirball Institute, New York University School of Medicine, New York, New York

The vertebrate intestinal tract is colonized by hundreds of species of bacteria that outnumber the total cells in the host, yet must be compartmentalized and tolerated to prevent invasive growth and harmful inflammatory responses. Signaling initiated by commensal bacteria contributes to compartmentalization, preventing mononuclear phagocyte-mediated transport of the non-invasive bacteria to sites where adaptive immune responses can be induced, e.g. the mesenteric lymph nodes. Nevertheless, T cell responses against non-invasive commensals can occur, as exemplified by responses elicited by the segmented filamentous bacteria (SFB). SFB adhere to the epithelium in the terminal ileum of mice and induce differentiation of Th17 cells that contribute to autoimmune disease in susceptible mice. We found that intestinal Th17 cells from SFB-colonized mice have T cell antigen receptors (TCRs) largely specific for SFB proteins, suggesting that SFB antigen presentation occurs within a niche specialized for Th17 cell differentiation. Based on the mouse studies and evidence for Th17 cell involvement in rheumatoid arthritis (RA), we compared the fecal microbiomes of RA patients and healthy individuals, and found an over-representation of bacterial strains most closely related to Prevotella copri in newly-diagnosed untreated patients. The implications of how individual constituents of the microbiota contribute to the effector/memory T cell repertoire and to organ-specific autoimmune disease will be discussed.

*Additional abstract to follow.

Travel & Lodging

Our Location

The New York Academy of Sciences

7 World Trade Center
250 Greenwich Street, 40th floor
New York, NY 10007-2157
212.298.8600

Directions to the Academy

Hotels Near 7 World Trade Center

Recommended partner hotel

Club Quarters, World Trade Center
140 Washington Street
New York, NY 10006
Phone: 212.577.1133

The New York Academy of Sciences is a member of the Club Quarters network, which offers significant savings on hotel reservations to member organizations. Located opposite Memorial Plaza on the south side of the World Trade Center, Club Quarters, World Trade Center is just a short walk to the Academy.

Use Club Quarters Reservation Password NYAS to reserve your discounted accommodations online.

Other nearby hotels

Conrad New York

212.945.0100

Millenium Hilton

212.693.2001

Marriott Financial Center

212.385.4900

Club Quarters, Wall Street

212.269.6400

Eurostars Wall Street Hotel

212.742.0003

Gild Hall, Financial District

212.232.7700

Wall Street Inn

212.747.1500

Ritz-Carlton New York, Battery Park

212.344.0800